SiNtx Technologies SINT 深 沪
已收盘 08-15 16:00:00 美东时间
3.04
-0.010
-0.33%
华盛通- 最 高3.0781
- 今 开2.96
- 成交量 3.78万股
- 最 低 2.96
- 昨 收 3.05
- 总市值 837.70万
- 52周最高 8.5961
- 市盈率 静 --
- 换手率 1.37%
- 52周最低 1.71
- 委 比 20.12%
- 总股本 275.56万
- 历史最高 209400.00
- 量 比 0.78
- 振 幅 3.87%
- 历史最低 1.71
- 每 手 1
- 风险率 31.93%
个股概要
财务分析
公司资料
相关新闻
分红派息
- 分时图
- 日k
- 周k
- 月k
相关新闻
更多SINTX Provides Business Update Highlighting SiNAPTIC Acquisition and Commercialization Strategy
SINTX Technologies, Inc. (NASDAQ:SINT) ("SINTX" or the "Company"), an advanced ceramics innovator specializing in silicon nitride (Si₃N₄) for medical device applications, today issued a business update in connection with
08-15 19:14
SINTX Technologies Issues Business Update Following Strategic Realignment, Leadership Expansion, and SiNAPTIC Acquisition
SINTX Technologies has made significant strides in advancing its commercialization efforts and strategic direction. The company, which specializes in silicon nitride for medical devices, has completed the acquisition of SiNAPTIC Surgical, expanded its leadership team with MedTech experts, and streamlined operations to focus on high-margin opportunities. Over 50,000 spinal devices have been successfully implanted. SINTX has also exited low-margin ...
08-15 11:00
SINTX Technologies Q2 EPS $(0.91) Misses $(0.79) Estimate, Sales $151.000K Miss $400.000K Estimate
SINTX Technologies (NASDAQ:SINT) reported quarterly losses of $(0.91) per share which missed the analyst consensus estimate of $(0.79) by 15.19 percent. This is a 74.79 percent increase over losses of $(3.61) per share
08-15 04:39
SINTX Technologies Says Peer-Reviewed Study Validates Silicon Nitride Coatings On CFR-PEKK Trauma Plates, Expanding Biomaterial Platform Into Hybrid Polymer-Carbon-Ceramic Constructs
SINTX Technologies, Inc. (NASDAQ:SINT) ("SINTX" or the "Company"), an advanced ceramics innovator specializing in silicon nitride (Si₃N₄) for musculoskeletal applications, today announced the publication of a
08-04 19:18
SINTX Technologies Expands Silicon Nitride Platform into Hybrid CFR-PEKK Trauma Plates
SINTX Technologies published a study in <em>Journal of the Mechanical Behavior of Biomedical Materials</em> validating silicon nitride (Si₃N₄) surface coatings on carbon fiber-reinforced polyetherketoneketone (CFR-PEKK) trauma plates. This marks a significant expansion of SINTX’s biomaterial platform. The research, supported by the NIH, was conducted in partnership with Drexel University. Key findings include mechanical tunability, preservation o...
08-04 11:00
SINTX Technologies Submits FDA 510(k) for Silicon Nitride Foot & Ankle Medical Devices
SINTX Technologies has submitted a 510(k) notification to the FDA for its novel silicon nitride osteotomy wedges, marking its entry into the foot and ankle reconstruction market. The devices, made from SINTX's proprietary silicon nitride, offer clinical advantages including bone repair promotion, antibiotic resistance without additives, and improved imaging clarity. The global foot and ankle fusion market is valued at $750.5 million and projected...
07-22 11:00
12 Health Care Stocks Moving In Monday's Pre-Market Session
Gainers Sonnet BioTherapeutics (NASDAQ:SONN) shares rose 239.4% to $17.55 dur...
07-14 20:08
Sintx Technologies Acquires Sinaptic Surgical Assets
The latest update is out from Sintx Technologies ( ($SINT) ). On June 23, 2025,...
06-28 04:58
SINTX Technologies Acquires SiNAPTIC Surgical Assets Including Patented Implants; Issues $750K Shares And 325K Warrants
Strategic Acquisition Brings Patented Implant Designs, Seasoned Executive Team, and Near-Term Commercial OpportunitiesSALT LAKE CITY, Utah, June 24, 2025 (GLOBE NEWSWIRE) -- SINTX Technologies, Inc. (NASDAQ:SINT)
06-24 20:40
SINTX Technologies Acquires SiNAPTIC Surgical Assets and IP to Expand into $1.3B Foot and Ankle Fusion Market
SINTX Technologies announced the acquisition of SiNAPTIC Holdings' surgical business assets, including intellectual property and six differentiated foot and ankle implant systems. The deal aims to expand SINTX's product portfolio and accelerate commercial growth in the foot and ankle fusion market, valued at $750.5 million and projected to reach $1.38 billion by 2032. Key SiNAPTIC executives will join SINTX, bringing expertise in product developm...
06-24 12:30
